SEC FIlings

23 Jan

SEC FIlings

General statement of acquisition of beneficial ownership

January 23, 2023
Posted by Ulisses

20 Jan

SEC FIlings

Notice of Effectiveness

January 23, 2023
Posted by Ulisses

20 Jan

SEC FIlings

424B3: Prospectus [Rule 424(b)(3)]

January 22, 2023
Posted by Ulisses

17 Jan

SEC FIlings

424B3: Prospectus [Rule 424(b)(3)]

January 17, 2023
Posted by Ulisses

17 Jan

SEC FIlings

424B3: Prospectus [Rule 424(b)(3)]

January 17, 2023
Posted by Ulisses

17 Jan

SEC FIlings

Securities and Exchange Commission

January 17, 2023
Posted by Ulisses

17 Jan

SEC FIlings

Securities and Exchange Commission

January 17, 2023
Posted by Ulisses

17 Jan

SEC FIlings

Current report

January 17, 2023
Posted by Ulisses

12 Jan

SEC FIlings

General form for registration of securities under the Securities

January 12, 2023
Posted by Ulisses

09 Jan

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 9, 2023
Posted by Ulisses

General statement of acquisition of beneficial ownership

Notice of Effectiveness

424B3: Prospectus [Rule 424(b)(3)]

424B3: Prospectus [Rule 424(b)(3)]

424B3: Prospectus [Rule 424(b)(3)]

Securities and Exchange Commission

Securities and Exchange Commission

Current report

General form for registration of securities under the Securities

Prospectus [Rule 424(b)(3)]

Gloperba Launch – Nasdaq-2024

A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain

Gout Awareness Day – May 22

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch